UPDATE: Perrigo Announces the Launch of Loratadine-D 12 Store Brand Labels
Perrigo Company (Nasdaq: PRGO) announced that it has begun shipping Loratadine-D 12 hour extended release tablets, the store brand equivalent to Schering-Plough's Claritin-D® 12 hour extended release tablets.
Claritin-D® 12 is indicated for the treatment of nasal allergy symptoms. Its estimated annual sales are approximately $111 million, according to data provided by Wolters, Kluwer.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.